m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05818
 [1]
m6A modification PVT1 PVT1 YTHDF2 : m6A sites Direct Inhibition Non-coding RNA PVT1 Regulated Target  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
m6A Target Pvt1 oncogene (PVT1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Pvt1 oncogene (PVT1) LncRNA View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary YTHDF2 plays a key role in maintaining the stability of Pvt1 oncogene (PVT1), mediated by ALKBH5, while PVT1-induced autophagy protects hippocampal neurons against synaptic plasticity loss and apoptosis, ultimately reducing cognitive deficits associated with diabetes.YTHDF2 may influence cognitive dysfunction in diabetes through several pathways, including the modulation of the PI3K/Akt pathway
Responsed Disease Diabetic encephalopathy ICD-11: 8E47
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
8E47: Diabetic encephalopathy 5 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Fosdenopterin Phase 2 [2]
Synonyms
CPMP; CPMP (molybdenum cofactor deficiency), Alexion; CPMP (molybdenum cofactor deficiency), Orphatec
    Click to Show/Hide
External Link
CID: 135463437
TTD: D07GTW
 Compound Name SA-237 Phase 3 [3]
Synonyms
Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai
    Click to Show/Hide
External Link
TTD: D0Y1ZU
 Compound Name BQ788 Phase 3 [4]
Synonyms
(2R)-2-[[(2R)-2-amino-3-(1-methoxycarbonylindol-3-yl)propanoyl]-[(2S)-2-[[(2R,6S)-2,6-dimethylpiperidine-1-carbonyl]amino]-4,4-dimethylpentanoyl]amino]hexanoic acid; BQ 788; AC1MIWQ3; GTPL1010; SCHEMBL18429752
    Click to Show/Hide
External Link
CID: 16759603
TTD: D08IXA
 Compound Name MEDI-551 Phase 2 [3]
External Link
TTD: D0R3ZE
 Compound Name PU-AD Phase 1 [5]
External Link
TTD: D0V9MT
References
Ref 1 Biological functions of the m6A reader YTHDF2 and its role in central nervous system disorders. Biochem Pharmacol. 2024 Dec;230(Pt 1):116576. doi: 10.1016/j.bcp.2024.116576. Epub 2024 Oct 16.
Ref 2 ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health.
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)